Q2e: 21% ARR growth and adj. EBITDA of DKK 1.1m. '24e likely to be even more back-end loaded vs. previous years. Adj. EBITDA up 6-4% in '24e-'26e, FVR of DKK 6-14.
23% ARR growth: strong new sales, with churn and uplift weaker, but one-time effects meant it was not that shabby after all. '24e-'26e EBITDA up 1-7% (low numbers): FVR kept at DKK 6-14
Q1e: We expect 25% ARR growth and adj. EBITDA of DKK -1.9m. Likely to reiterate FY'24 guidance with no material change in demand. FTE reduction lifts '24e-'26e adj. EBITDA by 19-5%.
Q3 ARR ~2% lower vs. ABGSCe, adj. EBITDA better Reiterated guidance requires strong ARR growth in Q4 Long-term case intact: a quality offering in large markets
We expect Q3 ARR of DKK 67m, ’22e ARR of DKK 70m Short-term headwinds; we cut ’22e-‘24e ARR by 10-22% Still a strong long-term case; high growth should return
DKK 60m raise vs. its own ambition of just DKK 20-40m Current guidance assumes no growth-fueling capital raise Cash is abundant on our ests. - M&A on the horizon?